AVXL Stock Down -17% after 6-Day Loss Streak
Anavex Life Sciences (AVXL) stock hit day 6 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -17% return. The company has lost about $136 Mil in value over the last 6 days, with its current market capitalization at about $806 Mil. The stock remains 12.1% below its value at the end of 2024. This compares with year-to-date returns of 9% for the S&P 500.
AVXL provides development of drug candidates for CNS diseases, including a Phase III Alzheimer’s treatment and a Phase I drug for frontotemporal dementia and other dementia indications. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell AVXL.
Comparing AVXL Stock Returns With The S&P 500
The following table summarizes the return for AVXL stock vs. the S&P 500 index over different periods, including the current streak:
- Rocket Lab Stock’s Next Leg Rides On A Vehicle That Has Not Flown Yet
- What The Headline Growth Rate Hides About JNJ Stock
- What Quadrupled Intel Stock Was Not Foundry Customers
- Netflix Stock Has Fallen On Slowing Sales While Margin And Buybacks Compound Earnings
- A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17%
- A 7-Day Winning Streak Has Boston Scientific Stock Up 8.6%
| Return Period | AVXL | S&P 500 |
|---|---|---|
| 1D | -1.6% | -0.6% |
| 6D (Current Streak) | -16.8% | 0.6% |
| 1M (21D) | -15.4% | 1.7% |
| 3M (63D) | 11.8% | 7.5% |
| YTD 2025 | -12.1% | 9.0% |
| 2024 | 15.4% | 23.3% |
| 2023 | 0.5% | 24.2% |
| 2022 | -46.6% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: AVXL Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 44 S&P constituents with 3 days or more of consecutive gains and 32 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 28 | 8 |
| 4D | 4 | 20 |
| 5D | 3 | 3 |
| 6D | 7 | 1 |
| 7D or more | 2 | 0 |
| Total >=3 D | 44 | 32 |
Key Financials for Anavex Life Sciences (AVXL)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-55.7 Mil | $-52.8 Mil |
| Net Income | $-47.5 Mil | $-43.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-12.4 Mil | $-14.3 Mil |
| Net Income | $-11.2 Mil | $-13.2 Mil |
The losing streak AVXL stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.